PureTech Capital Markets Meeting in London 9 May
PureTech Health Annual Capital Markets Meeting, London
Tuesday 9 May 2017
PureTech Health plc ("PureTech Health" or the "Company", LSE: PRTC), a cross-disciplinary biopharmaceutical company, announces its annual Capital Markets Meeting in London. The Company will discuss its near-term commercialisation and monetisation strategy as well as its growing research and development pipeline.
The meeting will take place in London on Tuesday 9 May 2017 from 13.00-17.00 BST and will feature PureTech Health presenters including members of the Company's Board of Directors and key scientific advisors.
Presenters at the event will include:
|
· |
Daphne Zohar, Co-Founder and CEO of PureTech Health |
|
· |
Bharatt Chowrira, PhD, JD, President and Chief of Business and Strategy of PureTech Health, former President of Synlogic and former Chief Operating Officer of Auspex Pharmaceuticals (acquired by Teva Pharmaceuticals) |
|
· |
Joseph Bolen, PhD, Chief Scientific Officer of PureTech Health; former President and Chief Scientific Officer at Moderna Therapeutics and former Chief Scientific Officer at Millennium Pharmaceuticals (acquired by Takeda) |
|
· |
Atul Pande, MD, Chief Medical Officer of PureTech Health, former SVP and Head of Neuroscience at GlaxoSmithKline |
|
· |
Christopher Viehbacher, Independent Non-Executive Director of PureTech Health; former CEO of Sanofi |
|
· |
Raju Kucherlapati, PhD, Independent Non-Executive Director, Scientific Advisory Board Member of PureTech Health; Co-Founder of Millennium Pharmaceuticals and Abgenix |
|
· |
John LaMattina, PhD, Independent Non-Executive Director of PureTech Health; former President of Pfizer Global Research and Development |
|
· |
Ben Shapiro, MD, Co-Founder & Non-Executive Director of PureTech Health; former Executive Vice President of Research for Merck |
|
· |
Marjorie Scardino, Senior Independent Director of PureTech Health; former CEO of The Economist and of Pearson plc, Chairman of the MacArthur Foundation Board |
|
· |
Dennis A. Ausiello, M.D., PureTech Health Scientific Advisory Board, Lead Director at Pfizer, former Chief of Medicine at Massachusetts General Hospital (Harvard) |
|
· |
Members of the PureTech Health leadership team and senior leaders of Akili, Karuna, Gelesis, Vedanta and other PureTech Health platform companies |
Please confirm if you would like to attend to PureTech.Event@fticonsulting.com
About PureTech Health
PureTech Health (PureTech Health plc, PRTC.L) is a cross-disciplinary biopharmaceutical company creating 21st century medicines that modulate the adaptive human systems. Our therapies target the immune, nervous, and gastro-intestinal systems by addressing the underlying pathophysiology of disease from a systems perspective rather than through a single receptor or pathway. We have multiple human proof-of-concept studies and pivotal or registration studies expected to read out in the near-term. PureTech Health's rich and growing research and development pipeline has been developed in collaboration with some of the world's leading scientific experts who, along with PureTech's experienced team and board, analyse more than 650 scientific discoveries per year to identify and advance only the opportunities we believe hold the most promise for patients. This team and process place PureTech Health on the cutting edge of ground-breaking science and technological innovation and leads the Company between and beyond existing disciplines. For more information, visit www.puretechhealth.com or connect with us on Twitter.
Forward Looking Statement
This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
|
|
PureTech Health |
FTI Consulting |
|
|
Allison Mead +1 617 651 3156 amead@puretechhealth.com |
Ben Atwell, Matthew Cole +44 (0) 20 3727 1000 |
This information is provided by RNS
Latest directors dealings
- 2 days ago Savannah Energy
- 2 days ago Buccaneer Energy PLC
- 2 days ago Savannah Energy
- 2 days ago Carclo
- 2 days ago Schroder Japan Growth Fund